Katherine McCalla Gilliatt
Family · Bedford, INNPI 1831337682
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 96 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $807, 2.5 times the $321 reported in 2023.
Across 96 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$371
- Lilly USA, LLC$159
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$154
- Exact Sciences$111
- Axsome Therapeutics, Inc.$108
- Lundbeck LLC$101
- plus $710 from 14 others
What the payments were for
- Food & beverage$1,715100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$1,715 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 38 | $41,809 |
| MounjaroTirzepatide | 30 | $29,468 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $25,560 |
| TrulicityDulaglutide | 20 | $20,128 |
| EliquisApixaban | 13 | $18,775 |
| RexultiBrexpiprazole | 12 | $17,957 |
| JardianceEmpagliflozin | 18 | $17,899 |
| PentasaMesalamine | 12 | $17,255 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $11,280 |
| FarxigaDapagliflozin Propanediol | 15 | $8,590 |
| XareltoRivaroxaban | 12 | $7,052 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 44 | $4,689 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 107 | $2,425 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 18 | $2,332 |
| Gabapentin | 140 | $2,167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $159 | $49,59750 claims |
| Novo NordiskOzempic | $84 | $41,80938 claims |
| PfizerEliquis | $47 | $18,77513 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $99 | $17,95712 claims |
| Boehringer IngelheimJardiance | $21 | $17,89918 claims |
| AstraZenecaFarxiga | $58 | $8,59015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.
Other family in Bedford
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.